The AMR Narrative

Carbapenem-resistant Klebsiella pneumoniae (CR-Kpn)

Although great care has been taken in the compilation and preparation of all directory entries to ensure accuracy, we cannot accept responsibility for any errors or omissions. Any medical information is provided for education/information purposes only and is not designed to replace medical advice by a qualified medical professional. Please see our disclaimer at the bottom of this entry.


What is carbapenem-resistant Klebsiella pneumoniae (CR-Kpn)?

Carbapenem-resistant Klebsiella pneumoniae (CR-Kpn) is a type of Klebsiella pneumoniae resistant to carbapenems, a type of last-line antibiotics used to treat serious multidrug-resistant bacterial infections.

Klebsiella pneumoniae has the ability to develop resistance through diverse mechanisms. CR-Kpn bacteria can produce substances (called carbapenemases) that break down carbapenems and other so-called beta-lactams antibiotics (such as penicillin), making these medications ineffective. Unfortunately, some CR-Kpn bacteria are even resistant to all available antibiotics, causing infections very difficult to treat.

Moreover, CR-Kpn can share its genetic code with other bacteria, rapidly spreading resistance. That is why it is considered a serious public health threat. As species included among the carbapenem-resistant Enterobacterales (CRE), CR-Kpn has been listed among the top priority bacterial pathogens to guide discovery, research and development of new antibiotics by the World Health Organization (WHO).

What is Klebsiella pneumoniae?

To understand CR-Kpn, it is important to know what Klebsiella pneumoniae is.

Klebsiella pneumoniae is a bacterium (bacteria), gram-negative, and rod-shaped. It belongs to the big order of the Enterobacterales, together with other species of bacteria, such as Escherichia coli. When Enterobacterales develop resistance to carbapenems, they are called carbapenem-resistant Enterobacterales (CRE), which include carbapenem-resistant Klebsiella pneumoniae (CR-Kpn), as well.

Klebsiella pneumoniae can cause different types of infection, including urinary tract infections, bloodstream infections, pneumonia, skin infections, and meningitis. Life-threatening conditions primarily occur in healthcare settings, such as hospitals and nursing homes, and affect people at high risk, such as those ones with a weakened immune system (see Who is at risk of a Klebsiella pneumoniae infection).

Where can Klebsiella pneumoniae be found?

Klebsiella pneumoniae are normally found in the large intestine, and in human stool (feces). Therefore, bacteria can colonize the gastrointestinal tract, living in a patient without causing symptoms or signs of infections.

However, when the bacteria enter the body, colonization can lead to infection especially in certain groups of people who are at greater risk than others.

How can Klebsiella pneumoniae spread?

Klebsiella pneumoniae bacteria can spread from person to person by skin contact with infected or colonized people (for example, through healthcare workers’ contaminated hands), or contaminated medical equipment or environmental surfaces.
Klebsiella pneumoniae infections are commonly acquired in healthcare facilities. Indeed, medical tools (such as urinary or intravenous catheters, or breathing tubes), and conditions (such as wounds caused by injury or surgery) may allow Klebsiella pneumoniae to enter the patient’s body and cause an infection.


Which infections can Klebsiella pneumoniae cause?

Healthy people usually do not get Klebsiella pneumoniae infections. However, these bacteria can cause life-threatening infections in people considered at risk.

These infections may include:

• Urinary tract infections, usually occurring in patients hospitalised with urinary catheters. Any part of urinary system can be infected, including kidneys (pyelonephritis), bladder (cystitis), and prostate (prostatitis).
• Bloodstream infection. When Klebsiella pneumoniae overcome the defence lines of the body, it can travel inside the bloodstream, causing bacteremia. It can turn into sepsis, an extreme and overactive response of the body to an infection, a life-threatening emergency which requires immediate treatment.
• Pneumonia. The infection of the lungs typically occurs in critically ill patients who require mechanical ventilation.
• Wound and surgical site infections. Klebsiella pneumoniae bacteria can infect skin, and even the tissues immediately beneath the skin. These conditions are more common in people with severe burns, and wounds due to surgery.
• Meningitis. In this life-threatening disease, bacteria can infect the meninges (the membranes covering the brain and spinal cord).

Who is at risk of a Klebsiella pneumoniae infection?

Anyone can develop a Klebsiella pneumoniae infection, but certain groups of people are at greater risk than others, including people:

• with chronic illnesses, such as cancer, diabetes, kidney, lung or liver diseases;
• with a weakened immune system, such as from HIV, immunosuppressants (medications which slow or stop the response of the immune system), or cancer chemotherapy;
• with urinary or intravenous catheters;
• with breathing tubes;
• with severe burns;
• with wounds due to injurie or surgical interventions;
• who are in healthcare facilities, such as hospitals;
• who received certain antibiotics for long periods of time.



How are Klebsiella pneumoniae infections diagnosed?

To correctly diagnose an infection caused by Klebsiella pneumoniae, first of all your physician will perform a physical examination and ask you about symptoms and risk factors. Guided by these elements, your doctor will be able to choose the most appropriate diagnostic tests.

Laboratory tests can identify Klebsiella pneumoniae using a sample taken from an area of the patient’s body likely to contain the microbe (for example, blood, urine, or other tissue or fluid). These samples are sent to a laboratory to grow the microorganism over time using a media on a petri dish (culture) and identify it.

Then susceptibility tests can be carried out to determine which antibiotics are most effective against it, to start the most appropriate antibiotic therapy. Understanding which antibiotic will work best is especially key to carbapenem-resistant Klebsiella pneumoniae (CR-Kpn) as this type of resistant Klebsiella pneumoniae bacteria may only respond to certain medicines. In some cases, they may respond to none.

Novel molecular DNA tests can not only rapidly detect the bacteria directly in a specimen but at same time provide antibiotic resistance results, making it much easier for the physician to choose appropriate antibiotics.

Finally, depending on the type of infection, your physician may recommend additional diagnostics, such as imaging tests.


How are Klebsiella pneumoniae infections treated?

As Klebsiella pneumoniae is a bacterium, therapy is represented by antibiotics. The antibiotic may vary according to the type and severity of the infection, and the results of susceptibility tests. Indeed, some infections, such as those ones caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kpn), are resistant to several antibiotics.

Intravenous antibiotics (medication given through a drip or a tube) are used in case of serious infections, which require to be treated in hospital and need additional therapies, too.

Unfortunately, due to the increasing resistance to the available antibiotics, Klebsiella pneumoniae infections are becoming more and more difficult to treat, and sometimes a combination therapy is needed (this means that two or even three antibiotics may be necessary).


How can Klebsiella pneumoniae infections be prevented?

Following these precautions can lower your risk of getting a Klebsiella pneumoniae infection. Moreover, they help to reduce your chances of spreading bacteria to others, as well.

• Wash your hands thoroughly and regularly with soap and running water. Then dry them with a clean towel, or a disposable paper towel. If you are not able to wash your hands, you can use an alcohol-based hand sanitizer. Keeping your hands clean is particularly important after using the bathroom, before and after handling medical devices or caring for wounds, and before preparing or eating food. Remember: hand hygiene is your best protection against infections.
• Frequently clean surfaces of the home, such as bathrooms, and use disinfecting products to clean especially high-touch surfaces, for example your cell phone, doorknobs, bedside tables, and light switches.
• Wearing gloves if your hands may come in contact with body fluids, stool or bandages from infected wounds. Always wash your hands after removing gloves.



Disclaimer: The information provided on this website is intended for educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Reliance on any information provided on this website is solely at your own risk. The website owners and authors are not responsible for any errors or omissions in the content or for any actions taken based on the information provided. It is recommended that you consult a qualified healthcare professional for individualised medical and health-related guidance.



Chris Shaffer

Chris Shaffer was a music, special education teacher, and high school principal for 45 years. At the end of his educational career, he was thrust into the world of AMR infections when a number of abdominal surgeries left him with an E-coli infection which failed to respond to antibiotics. After doctors in the USA left him with little hope for a cure, diminishing health, and a bleak prognosis, he set out on his own.

Chris found success in phage therapy at the Eliava Phage Therapy Center in Tbilisi, Georgia. With phage therapy giving Chris his life back, he has dedicated his retirement years to advocating for and helping raise awareness of phage therapy used for AMR infections. He tells the story of his phage journey in a book titled, Finding Phage: How I Partnered with a Friendly Virus to Cure My Deadly Bacterial Superinfection. His website, phagetherpyusa.com helps others learn to understand the healing power of phage therapy.

Demi Christofi

Demi is an Associate Scientific Director at a medical communications agency, with a background in microbiology and a longstanding focus on antimicrobial resistance. She holds an MSc in Microbiology, where she first became interested in the global challenge of resistance and the need to bring scientific understanding to wider audiences.

Demi’s career has centred on a simple but powerful belief: that how we communicate science matters. Her work focuses on making complex data clear, engaging, and accessible – whether for healthcare professionals, policy makers, or the patients most affected by infection and resistance. She has contributed to a wide range of AMR-focused projects, including educational programmes, congress communications and stewardship initiatives.

A central thread in Demi’s work is the importance of the patient voice. She is passionate about making sure real-world experiences of treatment failure, recurrent infections, and the anxiety surrounding resistance are not lost in the data. She believes that listening to patients and involving them meaningfully is essential for shaping more effective, human-centred responses to AMR.

Demi is also a strong advocate of the One Health approach, recognising AMR as a complex, interconnected issue that spans human health, animal health, and the environment. She is particularly drawn to efforts that move beyond siloed thinking and focus on practical, joined-up solutions.

In 2025, Demi joined The AMR Narrative as an Independent Advisor, where she supports the charity’s mission to centre communication, community, and inclusion in the global AMR response.

Outside of work, she is a Girlguiding unit leader and a qualified yoga teacher. These roles reflect her commitment to care, learning, and creating supportive spaces for others.

Andrea Hartley

Andrea has worked in health communications and campaigning for 3 decades. She is committed to fighting AMR through timely and appropriate communications globally,.

Andrea set up Skating Panda, the creative social and environmental impact consultancy, over a decade ago and drives its impact and growth. Focused on original and lasting public interest communications as well as issue strategy and advocacy, the Panda team has a track record of prompting tipping points in the status quo that drive better social and planetary outcomes.

Andrea’s combination of commercial marketing and development experience with deep issue knowledge have been sought by decision-makers at global summits, corporate and NGO board members, and have enabled her to set up multi-million fundraising platforms and push through policies that change and save lives. 

Andrea is Vice Chair of mothers2mothers, the world’s largest employer of women living with HIV, and a Board Director of Maymessy, a food poverty social enterprise.

A lifelong advocate for gender equality, she played a key role in establishing the UK’s Women’s Equality Party.

Esmita Charani

Professor Esmita Charani is a pharmacist and researcher investigating how we use antibiotics in different cultural and social contexts. She works with teams in the UK, India, and South Africa to develop research programmes investigating all aspects of antimicrobial resistance in human populations with a focus in hospital settings.

She has experience in communicating her research with patients and the public through various media including animations, blogs, and educational videos.